Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas

Pezzilli, Raffaele; Campana, Davide; Morselli-Labate, Antonio M.; Fabbri, Maria C.; Brocchi, Emilio; Tomassetti, Paola; de Jong, Koert P.; Rodriguez, Damian Casadesus
October 2009
World Journal of Gastroenterology;10/28/2009, Vol. 15 Issue 40, p5067
Academic Journal
AIM: To assess the patient-reported outcomes (PROs) of pancreatic neuroendocrine tumor (PNET) patients. METHODS: Fifty-one consecutive patients (21 male, 30 female, 61.0 ± 10.3 years) with proven PNETs were studied. An SF-12 questionnaire capable of exploring the physical (PCS) and mental (MCS) aspects of daily life was used. Four questionnaires were also used [12 items General Health Questionnaire (GHQ-12) for nonpsychotic psychiatric disorders, State Trait Anxiety Inventory (STAI) Y-1 and Y-2 for anxiety and BDI-? for depressive symptoms] to explore the psychological aspects of the disease. Forty-four sex- and age-matched Italian normative subjects were included and evaluated using the SF-12, STAI Y-1 and Y-2 questionnaires. RESULTS: Seven patients refused to participate to the study; they were clinically similar to the 44 participants who agreed to complete the questionnaires. PNET patients had a PCS score (44.7 ± 11.0) were not significantly different from the norms (46.1 ± 9.9, P = 0.610), whereas the MCS score was significantly lower in patients (42.4 ± 13.0) as compared to the norms (48.2 ± 9.8, P = 0.036). GHQ-12 identified 11 patients (25.0%) as having non-psychotic psychiatric disorders. The STAI scores were similar in the patients and in the normative population. Finally, BDI-? identified eight patients (18.2%) with moderate depression and 9 (20.5%) with mild depression whereas 27 patients (61.4%) had no depression. CONCLUSION: The PNET patients had a good physical but an impaired mental component of their quality of life; in addition, mild or moderate depressive symptoms are present in about 40% of PNET patients.


Related Articles

  • Diagnosis of neuroendocrine tumours by retrospective image fusion:is there a benefit? Amthauer, H.; Ruf, J.; Böhmig, M.; Lopez-Hänninen, E.; Rohlfing, T.; Wernecke, K.-D.; Plöckinger, U.; Gutberlet, M.; Lemke, A.-J.; Steinmüller, T.; Wiedenmann, B.; Felix, R. // European Journal of Nuclear Medicine & Molecular Imaging;2004, Vol. 31 Issue 3, p342 

    This study evaluated the use of image fusion in the preoperative staging of neuroendocrine tumors (NET) of the pancreas and the gastrointestinal tract (GIT). Thirty-eight patients suffering from a metasta- sized NET with location of the primary in the pancreas (n=15) or the GIT (n=23) were...

  • Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour,visualised with 68 Ga-DOTATOC PET. Henze, Marcus; Schuhmacher, Jochen; Dimitrakopoulou-Strauss, Antonia; Strauss, Ludwig G.; Mäcke, Helmut R.; Eisenhut, Michael; Haberkorn, Uwe // European Journal of Nuclear Medicine & Molecular Imaging;2004, Vol. 31 Issue 3, p466 

    Presents the case of a patient with exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumor. Confirmation of the tumors by histology; Classification of the tumor as borderline between 1a and 1b; Increase in the gene expression for somatostatin receptor subtype...

  • A rare case of metastasized non-functional pancreatic neuroendocrine tumor with a good long-term survival. Mirică, A.; Bădărău, I. A.; Mirică, R.; Păun, S.; Păun, D. L. // Journal of Medicine & Life;Oct-Dec2016, Vol. 9 Issue 4, p369 

    Background: Non-functional neuroendocrine tumors of the pancreas (NF-pNETs) are a varied group of extremely rare malignancies. The majority of patients already have liver metastases at the diagnosis moment, thus, treatment options are restricted, and the survival rate is reserved. Case report:...

  • Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Jiménez-Fonseca, P.; Carmona-Bayonas, A.; Martín-Pérez, E.; Crespo, G.; Serrano, R.; Llanos, M.; Villabona, C.; García-Carbonero, R.; Aller, J.; Capdevila, J.; Grande, E. // Cancer & Metastasis Reviews;Sep2015, Vol. 34 Issue 3, p381 

    Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms capable of producing hormones. The development of new treatments has improved progression-free survival, albeit with increased toxicity. Health-related quality of life (HRQoL) has become an important endpoint in clinical...

  • Focal uptake of Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Al-Ibraheem, Akram; Bundschuh, Ralph; Notni, Johannes; Buck, Andreas; Winter, Anna; Wester, Hans-Jürgen; Schwaiger, Markus; Scheidhauer, Klemens // European Journal of Nuclear Medicine & Molecular Imaging;Nov2011, Vol. 38 Issue 11, p2005 

    Purpose: Neuroendocrine tumours are frequently located in the upper abdomen and especially in the pancreas. Imaging of the abdomen with somatostatin analogs such as Ga-DOTA-Phe-Tyr-octreotide (DOTATOC) is a standard approach for imaging neuroendocrine cancer, but is still challenging due to...

  • Neuroendocrine tumors.  // Annals of Oncology;Oct2010 Supplement 8, Vol. 21 Issue suppl_8, pviii264 

    No abstract available.

  • Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with 68Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy. Luboldt, Wolfgang; Hartmann, Holger; Wiedemann, Bärbel; Zöphel, Klaus; Luboldt, Hans-Joachim // Molecular Imaging;Nov/Dec2010, Vol. 9 Issue 6, p351 

    No abstract available.

  • Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. Ito, Tetsuhide; Igarashi, Hisato; Jensen, Robert // Journal of Gastroenterology;Sep2012, Vol. 47 Issue 9, p941 

    Neuroendocrine tumors (NETs) [carcinoids, pancreatic neuroendocrine tumors (pNETs)] are becoming an increasing clinical problem because not only are they increasing in frequency, but they can frequently present with advanced disease that requires diagnostic and treatment approaches different...

  • Current Management of Advanced Pancreatic Neuroendocrine Tumors. Chan, Jennifer A.; Kulke, Matthew H. // European Journal of Clinical & Medical Oncology;2011, Vol. 3 Issue 1, p51 

    Recent population-based studies demonstrate a rising incidence of pancreatic neuroendocrine tumors, likely due, in part, to increasing awareness and improved classification. A broad range of treatment options exist for patients with advanced pancreatic NET. These include surgical intervention,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics